戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e, and commitment to long-term treatment and medication compliance.
2 ave high OOP expenses, associated with lower medication compliance.
3 pect to the role of treatment attendance and medication compliance.
4  and patient education regarding dietary and medication compliance.
5 nhaler technique [0.53 (0.475; 0.585)], poor medication compliance [0.385 (-0.007; 0.777)], and gende
6 , antilymphocyte therapy, recipient age, and medication compliance (all P < 0.001).
7 ension patients was associated with improved medication compliance and reduced risk of stroke and CVD
8 fter transplantation is associated with poor medication compliance and this may increase risk of graf
9  treatment discontinuations, adverse events, medication compliance, and change in mood.
10 s strategies to enhance treatment retention, medication compliance, and outcome for naltrexone treatm
11                     The primary obstacles to medication compliance appear to be situational/environme
12 self-management plan use, inhaler technique, medication compliance) appear to be the predominant infl
13 complete the trial for personal reasons, and medication compliance averaged 90% in the remaining subj
14                Intensive efforts to increase medication compliance before month 8 posttransplantation
15  Text messaging emerged as a tool to enhance medication compliance, but a trial of twice-weekly text
16 ns impact patient safety when monitoring for medication compliance, drug substitution, or misuse/abus
17                             As an adjunct to medication compliance enhancement treatment, topiramate
18 arkers to assess appropriate drug dosage and medication compliance in patients undergoing primary che
19   These further underscore the importance of medication compliance in prevention of ABMR and possibly
20 s than placebo as an adjunct to standardised medication compliance management in treatment of alcohol
21 , and 75 had placebo and weekly standardized medication compliance management.
22 placebo as an adjunct to weekly standardised medication compliance management.
23 ve persistently poor control despite optimal medication compliance, newly emerging pharmaceuticals, i
24                                          The medication compliance of 77 homeless persons who had bee
25  no significant between-group differences in medication compliance or HRQOL.
26 R, 0.37; 95% CI, 0.15-0.90) and prescription medication compliance (OR, 0.35; 95% CI, 0.14-0.85).
27 ternative to "universal" DOT in managing the medication compliance problem when treating TB.
28                                              Medication compliance rates among a cohort of homeless p
29                         This study describes medication compliance rates among a group of homeless me
30 study completion, therapy participation, and medication compliance rates in the trial were high, with
31 y was defined by recruitment, retention, and medication compliance rates.
32 imulate the effect of environmental factors, medication compliance, seasonality, and medical history
33 ct data on demographics, travel destination, medication compliance, side effects, and reasons for cho
34                                              Medication compliance, the focus of most compliance-rela
35 epartment [ED] visits, hospitalizations, and medication compliance), training, customized patient edu
36                                              Medication compliance was associated with fewer psychiat
37                                              Medication compliance was measured by two items: 1) Freq
38                                              Medication compliance was monitored using a riboflavin m
39                                              Medication compliance was verified by observed capsule a
40 charge at individual (eg, behavioral issues, medication compliance, withholding information, refusal